Burczynska B, Madalinski K, Pawlowska J, Woynarowski M, Socha J, Gerlich W H, Willems W R, Wozniewicz B, Stachowski J
Department of Clinical Immunology, Child Health Center, Warsaw, Poland.
J Hepatol. 1994 Dec;21(6):1097-102. doi: 10.1016/s0168-8278(05)80624-5.
Serum concentrations of HBsAg, HBeAg and hepatitis B virus DNA were measured quantitatively before interferon treatment in 23 children (17 boys, 6 girls) suffering from chronic hepatitis B, and correlated to the outcome of the treatment. Five children remained HBsAg- and HBeAg-positive throughout the treatment and 6 months after the end of the treatment (non-responders), 12 children eliminated HBeAg but not HBsAg (partial responders) and six eliminated HBeAg and HBsAg (complete responders). The five non-responders had significantly higher initial HBsAg and HBeAg concentrations and significantly lower alanine aminotransferase levels than the partial or complete responders. The six complete responders had significantly lower HBsAg concentrations than the partial or non-responders, and seemed to be younger. No significant difference in HBV DNA levels was found in the three response groups. These data suggest that quantitative assays of HBsAg and HBeAg are particularly useful in selecting patients with chronic hepatitis B for interferon therapy.
对23名慢性乙型肝炎患儿（17名男孩，6名女孩）在进行干扰素治疗前定量检测血清中乙肝表面抗原（HBsAg）、乙肝e抗原（HBeAg）和乙肝病毒DNA水平，并将其与治疗结果相关联。5名儿童在整个治疗期间及治疗结束后6个月均保持HBsAg和HBeAg阳性（无应答者），12名儿童清除了HBeAg但未清除HBsAg（部分应答者），6名儿童清除了HBeAg和HBsAg（完全应答者）。5名无应答者的初始HBsAg和HBeAg浓度显著高于部分应答者或完全应答者，而谷丙转氨酶水平显著低于后者。6名完全应答者的HBsAg浓度显著低于部分应答者或无应答者，且年龄似乎更小。三组应答者的乙肝病毒DNA水平无显著差异。这些数据表明，HBsAg和HBeAg的定量检测在选择慢性乙型肝炎患者进行干扰素治疗方面特别有用。
